Lupus & antiphospholipid syndrome
Lupus nephritis outcomes in Aotearoa New Zealand, a retrospective case series
Authors' conclusion
In this LN cohort in Aotearoa New Zealand, half of people with LN class III/IV do not achieve early renal response and over one-third have poor outcomes over less than a decade of follow up. Subsidy of MMF substantively increased its use and patients in this time period had better rates of good LN outcomes.
Study context
- Population
- Adults with biopsy-confirmed LN, two regions of Aotearoa New Zealand74 class III/IV LN
- Participants
- 100 adults
- Exposure
- Class III/IV LN outcomes in the mycophenolate mofetil (MMF)-unrestricted vs MMF-restricted period
- MMF-UNRESTRICTED PERIODn = 46
- MMF-RESTRICTED PERIODn = 28reference
- Outcome
- MMF use for induction in class III/IV LN
Methodological detailstwo regions, 18-year period
- Two regions
- 18-year period
Main finding
As reported in the abstract
P = 0.01
Observational data: associations, not effects.
Further findings
High dose CYC use
Complete response (CR)
P = 0.08
Overall renal response (ORR; at least PR, KDIGO)
P = 0.37
Poor outcomes with no renal response, class III/IV LN · last-observed follow up (mean 7 years from biopsy)
- Poor outcomes with no renal response
- 26/74 (36% cases)
Original publication
Lupus nephritis outcomes in Aotearoa New Zealand, a retrospective case series. Lupus. Published 23 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →